HighTide Therapeutics rides NASH R&D wave with a $107M raise

Kyle LaHucik

Senior Reporter

HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

HighTide Therapeutics rides NASH R&D wave with a $107M raise

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

HighTide Therapeutics rides NASH R&D wave with a $107M raise